Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-10-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-06-358010PMID 21841163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

  2011cited by this paper
• Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients

  2011cited by this paper
• Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia

  2011cited by this paper
• Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

  2010cited by this paper
• Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

  2010cited by this paper
• Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.

  2009cited by this paper
• Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.

  2009cited by this paper
• Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG

  2009cited by this paper
• Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.

  2009cited by this paper
• A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

  2008cited by this paper
• Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

  2008cited by this paper
• Hematopoietic stem cell transplantation in adults with acute myeloid leukemia.

  2008cited by this paper
• Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.

  2007cited by this paper
• High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.

  2006cited by this paper
• Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

  2006cited by this paper
• Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

  2006cited by this paper
• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  2005cited by this paper
• Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.

  2005cited by this paper
• Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP)

  2005cited by this paper
• Outcome of patients with acute myelogenous leukemia after second salvage therapy

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

  2005cited by this paper
• Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?

  2005cited by this paper
• Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.

  2004cited by this paper
• Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience

  2003cited by this paper
• Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

  2003cited by this paper
• The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature

  2002cited by this paper
• Therapeutic options for acute myelogenous leukemia

  2001influential reference
• Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)

  2000cited by this paper
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

  2000cited by this paper
• Treatment of relapsed and refractory acute myelogenous leukemia

  2000cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper
• Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16).

  1994cited by this paper
• Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.

  1993cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper

• Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML

  2025cites this paper
• Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia

  2024influential citation
• Salvaging (with) CloBu4.

  2023cites this paper
• Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies.

  2022cites this paper
• Evolution and optimization of therapies for acute lymphoblastic leukemia in infants

  2022cites this paper
• Hand–foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients

  2021cites this paper
• Clofarabine and Treosulfan as conditioning for matched related and unrelated HSCT: results from the phase II trial "Clo3o".

  2020cites this paper
• Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies

  2020cites this paper
• Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer

  2020cites this paper
• Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.

  2019cites this paper
• Preparing the Patient for HSCT: Conditioning Regimens and Their Scientific Rationale

  2018cites this paper
• Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML

  2018cites this paper
• Clinical Use of Clofarabine for Adults and Children with Leukemia

  2017cites this paper
• Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT

  2017cites this paper
• A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

  2017cites this paper
• Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

  2017cites this paper
• HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy

  2017cites this paper
• Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia

  2017cites this paper
• Dose-finding designs for trials of molecularly targeted agents and immunotherapies

  2017cites this paper
• Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

  2016cites this paper
• Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.

  2016cites this paper
• Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia

  2016cites this paper
• Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

  2016cites this paper
• Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

  2016cites this paper
• UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.

  2016cites this paper
• Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

  2016cites this paper
• A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies.

  2016cites this paper
• Long-term Outcomes After Treatment with Clofarabine ± Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS

  2016cites this paper
• Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab

  2015cites this paper
• Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

  2015cites this paper
• Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma

  2015cites this paper
• Approach to patients with primary refractory acute myeloid leukemia

  2015cites this paper
• Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.

  2015cites this paper
• Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation

  2014cites this paper
• Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

  2014cites this paper
• A critical review of which children with acute myeloid leukaemia need stem cell procedures

  2014cites this paper
• Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis

  2014cites this paper
• Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia

  2013influential citation
• Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

  2013cites this paper
• Reduced Intensity Transplants for Lymphoma : Reduced Intensity versus Full Transplant 9

  2013cites this paper
• Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

  2013cites this paper
• Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: To Whom, When, and How

  2013cites this paper
• A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes

  2013cites this paper
• Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies

  2013cites this paper
• Looking toward the future: an individualized approach to allogeneic transplantation

  2013cites this paper
• Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia

  2013cites this paper
• High-dose etoposide in allogeneic stem cell transplantation

  2012cites this paper
• Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?

  2012cites this paper
• Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies

  2012cites this paper
• Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

  2012cites this paper
• Transplantation for AML in children.

  2012cites this paper
• Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?

  2012cites this paper
• Clofarabine‐containing conditioning regimen for allo‐SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT

  2011influential citation